Diagnosis and management of interstitial lung disease.

Transl Respir Med. 2: 4Lederer D.J. Martinez F.J.

Idiopathic Pulmonary Fibrosis.

N Engl J Med. 378: 1811-1823Cottin V. Hirani N.A. Hotchkin D.L. et al.

Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.

Eur Respir Rev. 27Oliveira D.S. Araujo Filho J.A. Paiva A.F.L. et al.

Idiopathic interstitial pneumonias: review of the latest American Thoracic Society/European Respiratory Society classification.

Radiol Bras. 51: 321-327Raghu G. Collard H.R. Egan J.J. et al.

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Am J Respir Crit Care Med. 183: 788-824American Thoracic Society

Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Am J Respir Crit Care Med. 161: 646-664Fell C.D. Martinez F.J. Liu L.X. et al.

Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis.

Am J Respir Crit Care Med. 181: 832-837Marinescu D.C. Raghu G. Remy-Jardin M. et al.

Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis.

Chest. 162: 614-629Kaunisto J. Salomaa E.R. Hodgson U. et al.

Idiopathic pulmonary fibrosis--a systematic review on methodology for the collection of epidemiological data.

BMC Pulm Med. 13: 53Raghu G. Weycker D. Edelsberg J. et al.

Incidence and prevalence of idiopathic pulmonary fibrosis.

Am J Respir Crit Care Med. 174: 810-816Raghu G. Chen S.Y. Yeh W.S. et al.

Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11.

Lancet Respir Med. 2: 566-572Nalysnyk L. Cid-Ruzafa J. Rotella P. et al.

Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature.

Eur Respir Rev. 21: 355-361Hutchinson J. Fogarty A. Hubbard R. et al.

Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.

Eur Respir J. 46: 795-806Swigris J.J. Olson A.L. Huie T.J. et al.

Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death.

Respir Med. 106: 588-593Adegunsoye A. Oldham J.M. Bellam S.K. et al.

African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis.

Eur Respir J. 51Selman M. King T.E. Pardo A.

American Thoracic S, European Respiratory S, American College of Chest P. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.

Ann Intern Med. 134: 136-151Hecker L. Thannickal V.J.

Nonresolving fibrotic disorders: idiopathic pulmonary fibrosis as a paradigm of impaired tissue regeneration.

Am J Med Sci. 341: 431-434

Antioxidant therapy for idiopathic pulmonary fibrosis.

N Engl J Med. 353: 2285-2287Fries K.M. Blieden T. Looney R.J. et al.

Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis.

Clin Immunol Immunopathol. 72: 283-292Adegunsoye A. Vij R. Noth I.

Integrating Genomics Into Management of Fibrotic Interstitial Lung Disease.

Chest. 155: 1026-1040

Familial Pulmonary Fibrosis: Genetic Features and Clinical Implications.

Chest. 160: 1764-1773Wang Y. Kuan P.J. Xing C. et al.

Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer.

Am J Hum Genet. 84: 52-59van Moorsel C.H. van Oosterhout M.F. Barlo N.P. et al.

Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort.

Am J Respir Crit Care Med. 182: 1419-1425Seibold M.A. Wise A.L. Speer M.C. et al.

A common MUC5B promoter polymorphism and pulmonary fibrosis.

N Engl J Med. 364: 1503-1512Vicary G.W. Vergne Y. Santiago-Cornier A. et al.

Pulmonary Fibrosis in Hermansky-Pudlak Syndrome.

Ann Am Thorac Soc. 13: 1839-1846Snetselaar R. van Moorsel C.H.M. Kazemier K.M. et al.

Telomere length in interstitial lung diseases.

Chest. 148: 1011-1018Armanios M.Y. Chen J.J. Cogan J.D. et al.

Telomerase mutations in families with idiopathic pulmonary fibrosis.

N Engl J Med. 356: 1317-1326Iwai K. Mori T. Yamada N. et al.

Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure.

Am J Respir Crit Care Med. 150: 670-675Baumgartner K.B. Samet J.M. Stidley C.A. et al.

Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis.

Am J Respir Crit Care Med. 155: 242-248

The Role of Gastroesophageal Reflux and Microaspiration in Idiopathic Pulmonary Fibrosis.

Clin Pulm Med. 21: 81-85Baumgartner K.B. Samet J.M. Coultas D.B. et al.

Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers.

Am J Epidemiol. 152: 307-315

Is idiopathic pulmonary fibrosis an environmental disease?.

Proc Am Thorac Soc. 3: 293-298Sheng G. Chen P. Wei Y. et al.

Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis: A Meta-Analysis.

Chest. 157: 1175-1187Raghu G. Remy-Jardin M. Myers J.L. et al.

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Am J Respir Crit Care Med. 198: e44-e68Moua T. Maldonado F. Decker P.A. et al.

Frequency and implication of autoimmune serologies in idiopathic pulmonary fibrosis.

Mayo Clin Proc. 89: 319-326Johnston I.D. Prescott R.J. Chalmers J.C. et al.

British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society.

Thorax. 52: 38-44Muller N.L. Guerry-Force M.L. Staples C.A. et al.

Differential diagnosis of bronchiolitis obliterans with organizing pneumonia and usual interstitial pneumonia: clinical, functional, and radiologic findings.

Radiology. 162: 151-156Souza C.A. Muller N.L. Flint J. et al.

Idiopathic pulmonary fibrosis: spectrum of high-resolution CT findings.

AJR Am J Roentgenol. 185: 1531-1539Orens J.B. Kazerooni E.A. Martinez F.J. et al.

The sensitivity of high-resolution CT in detecting idiopathic pulmonary fibrosis proved by open lung biopsy. A prospective study.

Chest. 108: 109-115Lynch D.A. Newell J.D. Logan P.M. et al.

Can CT distinguish hypersensitivity pneumonitis from idiopathic pulmonary fibrosis?.

AJR Am J Roentgenol. 165: 807-811Raghu G. Remy-Jardin M. Richeldi L. et al.

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Am J Respir Crit Care Med. 205: e18-e47Tomassetti S. Ravaglia C. Wells A.U. et al.

Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study.

Lancet Respir Med. 8: 786-794

Interstitial lung disease guideline.

Thorax. 63: v1-v58Hetzel J. Wells A.U. Costabel U. et al.

Transbronchial cryobiopsy increases diagnostic confidence in interstitial lung disease: a prospective multicentre trial.

Eur Respir J. 56Maldonado F. Danoff S.K. Wells A.U. et al.

Transbronchial Cryobiopsy for the Diagnosis of Interstitial Lung Diseases: CHEST Guideline and Expert Panel Report.

Chest. 157: 1030-1042Collard H.R. Tino G. Noble P.W. et al.

Patient experiences with pulmonary fibrosis.

Respir Med. 101: 1350-1354Ferreira A. Garvey C. Connors G.L. et al.

Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response.

Chest. 135: 442-447

Predictors of success in pulmonary rehabilitation for patients with interstitial lung disease.

Chest. 136: 1183-1184Zhao J. Metra B. George G. et al.

Mortality among Patients with COVID-19 and Different Interstitial Lung Disease Subtypes: A Multicenter Cohort Study.

Ann Am Thorac Soc. 19: 1435-1437Marcon A. Schievano E. Fedeli U.

Mortality Associated with Idiopathic Pulmonary Fibrosis in Northeastern Italy, 2008-2020: A Multiple Cause of Death Analysis.

Int J Environ Res Public Health. 18Levin M.J. Ustianowski A. De Wit S. et al.

Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.

N Engl J Med. 386: 2188-2200Raghu G. Rochwerg B. Zhang Y. et al.

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.

Am J Respir Crit Care Med. 192: e3-e19Carlos W.G. Strek M.E. Wang T.S. et al.

Treatment of Idiopathic Pulmonary Fibrosis.

Ann Am Thorac Soc. 13: 115-117

Therapeutic Approach to Adult Fibrotic Lung Diseases.

Chest. 150: 1371-1386Petnak T. Lertjitbanjong P. Thongprayoon C. et al.

Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.

Chest. 160: 1751-1763Wuyts W.A. Kolb M. Stowasser S. et al.

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of </=50 % of Predicted Value.

Lung. 194: 739-743Harari S. Caminati A. Poletti V. et al.

A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis.

Respiration. 95: 433-440Wollin L. Wex E. Pautsch A. et al.

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.

Eur Respir J. 45: 1434-1445Richeldi L. du Bois R.M. Raghu G. et al.

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

N Engl J Med. 370: 2071-2082Richeldi L. Cottin V. du Bois R.M. et al.

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS((R)) trials.

Respir Med. 113: 74-79Galli J.A. Pandya A. Vega-Olivo M. et al.

Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.

Respirology. 22: 1171-1178Harari S. Pesci A. Albera C. et al.

Nintedanib in IPF: Post hoc Analysis of the Italian FIBRONET Observational Study.

Respiration. 101: 577-584Raghu G. Johnson W.C. Lockhart D. et al.

Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study.

Am J Respir Crit Care Med. 159: 1061-1069Noble P.W. Albera C. Bradford W.Z. et al.

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.

Eur Respir J. 47: 243-253Valeyre D. Albera C. Bradford W.Z. et al.

Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.

Respirology. 19: 740-747Nathan S.D. Shlobin O.A. Weir N. et al.

Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium.

Chest. 140: 221-229Ley B. Ryerson C.J. Vittinghoff E. et al.

A multidimensional index and staging system for idiopathic pulmonary fibrosis.

Ann Intern Med. 156: 684-691Collard H.R. Ryerson C.J. Corte T.J. et al.

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.

Am J Respir Crit Care Med. 194: 265-275Ryerson C.J. Cottin V. Brown K.K. et al.

Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm.

Eur Respir J. 46: 512-520Durheim M.T. Collard H.R. Roberts R.S. et al.

Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.

Lancet Respir Med. 3: 388-396Paterniti M.O. Bi Y. Rekic D. et al.

Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.

Ann Am Thorac Soc. 14: 1395-1402Singh S.J. Puhan M.A. Andrianopoulos V. et al.

An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease.

Eur Respir J. 44: 1447-1478Holland A.E. Spruit M.A. Troosters T. et al.

An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease.

Eur Respir J. 44: 1428-1446Chambers D.C. Perch M. Zuckermann A. et al.

The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report - 2021; Focus on recipient characteristics.

J Heart Lung Transplant. 40: 1060-1072Chambers D.C. Cherikh W.S. Harhay M.O. et al.

The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match.

J Heart Lung Transplant. 38: 1042-1055Weill D. Benden C. Corris P.A. et al.

A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation.

J Heart Lung Transplant. 34: 1-15

Lung transplantation for interstitial lung disease.

Eur Respir Rev. 30Flaherty K.R. Wells A.U. Cottin V. et al.

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

N Engl J Med. 381: 1718-1727Wong A.W. Ryerson C.J. Guler S.A.

Progression of fibrosing interstitial lung disease.

Respir Res. 21: 32Wells A.U. Brown K.K. Flaherty K.R. et al.

What's in a name? That which we call IPF, by any other name would act the same.

Eur Respir J. 51Brown K.K. Martinez F.J. Walsh S.L.F. et al.

The natural history of progressive fibrosing interstitial lung diseases.

Eur Respir J. 55Karimi-Shah B.A. Chowdhury B.A.

Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.

N Engl J Med. 372: 1189-1191Akira M. Inoue Y. Arai T. et al.

Long-term follow-up high-resolution CT findings in non-specific interstitial pneumonia.

Thorax. 66: 61-65Silva C.I. Muller N.L. Hansell D.M. et al.

Nonspecific interstitial pneumonia and idiopathic pulmonary fibrosis: changes in pattern and distribution of disease over time.

Radiology. 247: 251-259Pugashetti J.V. Adegunsoye A. Wu Z. et al.

Validation of Proposed Criteria for Progressive Pulmonary Fibrosis.

Am J Respir Crit Care Med. 207: 69-76Khor Y.H. Farooqi M. Hambly N. et al.

Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions.

Am J Respir Crit Care Med. 207: 102-105Behr J. Prasse A. Kreuter M. et al.

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.

Lancet Respir Med. 9: 476-486Maher T.M. Corte T.J. Fischer A. et al.

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.

Lancet Respir Med. 8: 147-157